Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

著者: Michael W. Konstan, Edward F. McKone, Richard B. Moss, Gautham Marigowda, Simon Tian, David Waltz, Xiaohong Huang, Barry Lubarsky, Jaime Rubin, Stefanie J. Millar, David J. Pasta, Nicole Mayer-Hamblett, Christopher H. Goss, Wayne J. Morgan, Gregory S. Sawicki - The Lancet 2016 被引用: 286